Tempus, a leader in artificial intelligence and precision medicine, today announced the company will exhibit 20 abstracts at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting, which convenes from June 2-6, in Chicago, Illinois. This year, Tempus is presenting its latest research via two oral presentations, one poster discussion session, and several poster presentations. 

“Tempus is excited to be returning to ASCO to share our latest collaborative, scientific and clinical findings – research that is enabled by our AI-enabled precision medicine platform,” said Calvin Chao, MD, Senior Vice President of Medical Affairs at Tempus. “We look forward to presenting studies that demonstrate how the tumor-normal match feature of Tempus’ signature xT assay may detect germline alterations across different cancer types, and the various ways that information can be beneficial in informing patient care.”

Highlights from Tempus’ oral presentations and poster discussion session include:  

• Oral Presentation (10509): Effect of germline mutations shape somatic alteration landscapes in BRCA-associated cancers
  • Session Date & Time: Sunday, June 4, 2023; 4:30 – 6:00 p.m. CDT
  • Location: S100bc
  • Overview: Using Tempus’ multimodal real-world database, the team captured how germline mutations could shape the somatic alteration landscape in four BRCA-associated cancers (breast, ovarian, prostate, and pancreatic). Germline alterations in homologous recombination repair genes (gHRR) were detected in 4-6% of patients. The results of this study suggest that gHRR-mutated cancers have distinct genomic landscapes that may influence therapeutic considerations.
• Oral Presentation (10512): Germline alterations in patients with lung cancer
  • Session Date & Time: Sunday, June 4, 2023; 4:30 – 6:00 p.m. CDT
  • Location: S100bc
  • Overview: This study leveraged the Tempus multimodal real-world database to analyze 11,740 tumors from primary lung cancer patients. The team found infrequent pathogenic/likely pathogenic germline alterations identified through the tumor-normal match feature of the xT test present across different lung cancer subgroups, including for both smokers and non-smokers. This indicates that while lung cancer has not historically been considered for hereditary testing, there may be a subset of lung cancer patients with germline mutations that benefit from testing. 
• Poster Discussion (10522): Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers
  • Session Date & Time: Saturday, June 3, 2023; 4:30 – 6:00 p.m. CDT
  • Location: S102
  • Overview: Tempus leveraged its multimodal real-world database to compare the frequency of CHIP mutations for patients with and without germline HRR mutations in BRCA-associated cancers (breast, ovarian, prostate, and pancreatic), as captured using xT tumor-normal matched testing. The team found that patients with germline BRCA1 mutations had similar or higher levels of CHIP mutations compared to the sporadic group among breast and ovarian cancer types, despite having a lower median age of diagnosis. This indicates that gHRR mutations may influence the frequency of CHIP mutations in BRCA-associated cancer types. 

 
To learn more, visit https://www.tempus.com/events/asco-2023/. 

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.